Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin

Author:

Ferrannini Giulia1ORCID,Gerstein Hertzel2ORCID,Colhoun Helen Martina3ORCID,Dagenais Gilles R4,Diaz Rafael5,Dyal Leanne2,Lakshmanan Mark6,Mellbin Linda1,Probstfield Jeffrey7ORCID,Riddle Matthew Casey8,Shaw Jonathan Edward9ORCID,Avezum Alvaro10,Basile Jan Neil11,Cushman William C12,Jansky Petr13,Keltai Mátyás14,Lanas Fernando15ORCID,Leiter Lawrence Alan16ORCID,Lopez-Jaramillo Patricio17ORCID,Pais Prem18,Pīrāgs Valdis19,Pogosova Nana20ORCID,Raubenheimer Peter Johann21ORCID,Sheu Wayne Huey-Herng22,Rydén Lars1

Affiliation:

1. Department of Medicine K2, Karolinska Institutet, Solnavägen 1, Stockholm SE171 77, Sweden

2. Population Health Research Institute, McMaster University and Hamilton Health Sciences, 237 Barton Street East, Hamilton, ON L8L 2X2, Canada

3. Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road, Edinburgh EH4 2XU, UK

4. Department of Medicine, Institut Universitaire de Cardiologie et Pneumologie, Université Laval, Québec City, QC, Canada

5. ECLA, Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Paraguay 160, S2000 Rosario, Santa Fe, Argentina

6. Eli Lilly and Company, 893 Delaware St, Indianapolis, IN 46225, USA

7. Department of Medicine, RR-512, Health Sciences Building, University of Washington, Box 356420, 1959 NE Pacific Street, Seattle, WA 98195-6420, USA

8. Department of Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA

9. Baker Heart and Diabetes Institute, 75 Commercial Rd, Melbourne VIC 3004, Australia

10. Instituto Dante Pazzanese de Cardiologia and University Santo Amaro, Av. Dr. Dante Pazzanese, 500 - Vila Mariana, São Paulo - SP, 04012-909, Brazil

11. Division of Cardiology, Medical University of South Carolina, 171 Ashley Ave, Charleston, SC 29425, USA

12. Memphis Veterans Affairs Medical Center, Preventive Medicine Section, 1030 Jefferson Ave, Memphis, TN 38104, USA

13. Department of Cardiovascular Surgery, University Hospital Motol, V Úvalu 84 150 06 Praha 5, Czech Republic

14. Department of Cardiology, Semmelweis University, Hungarian Institute of Cardiology, Üllői út 26, 1085 Budapest, Hungary

15. Department of Internal Medicine, Universidad de La Frontera, Francisco Salazar 1145, Temuco, Araucanía, Chile

16. Department of Medicine, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, 38 Shuter St, Toronto, ON M5B 1A6, Canada

17. Masira Research Institute, Medical School, Universidad de Santander UDES, Calle 70 No 55-210 Bucaramanga, Colombia

18. Division of Clinical Research and Training, St. John's Research Institute, 100 Feet Rd, John Nagar, Koramangala, Bengaluru, Karnataka 560034, India

19. Department of Internal Medicine, Latvijas Universitate, Raiņa bulvāris 19, Centra rajons, Riga LV-1586, Latvia

20. National Medical Research Center of Cardiology, Ulitsa Ostrovityanova, 1, Moscow 117997, Russian Federation

21. Department of Medicine, University of Cape Town, Observatory, Cape Town 7925, South Africa

22. Department of Medicine, Taichung Veterans General Hospital, Rongguang Road, Puli Township, Nantou County, Taichung 54552, Taiwan

Abstract

Abstract Objective  Recent European Guidelines for Diabetes, Prediabetes and Cardiovascular Diseases introduced a shift in managing patients with type 2 diabetes at high risk for or established cardiovascular (CV) disease by recommending GLP-1 receptor agonists and SGLT-2 inhibitors as initial glucose-lowering therapy. This is questioned since outcome trials of these drug classes had metformin as background therapy. In this post hoc analysis, the effect of dulaglutide on CV events was investigated according to the baseline metformin therapy by means of a subgroup analysis of the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. Research design and methods  Patients in REWIND (n = 9901; women: 46.3%; mean age: 66.2 years) had type 2 diabetes and either a previous CV event (31%) or high CV risk (69%). They were randomized (1:1) to sc. dulaglutide (1.5 mg/weekly) or placebo in addition to standard of care. The primary outcome was the first of a composite of nonfatal myocardial infarction, nonfatal stroke, and death from cardiovascular or unknown causes. Key secondary outcomes included a microvascular composite endpoint, all-cause death, and heart failure. The effect of dulaglutide in patients with and without baseline metformin was evaluated by a Cox regression hazard model with baseline metformin, dulaglutide assignment, and their interaction as independent variables. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by a Cox regression model with adjustments for factors differing at baseline between people with vs. without metformin, identified using the backward selection. Results  Compared to patients with metformin at baseline (n = 8037; 81%), those without metformin (n = 1864; 19%) were older and slightly less obese and had higher proportions of women, prior CV events, heart failure, and renal disease. The primary outcome occurred in 976 (12%) participants with baseline metformin and in 281 (15%) without. There was no significant difference in the effect of dulaglutide on the primary outcome in patients with vs. without metformin at baseline [HR 0.92 (CI 0.81–1.05) vs. 0.78 (CI 0.61–0.99); interaction P = 0.18]. Findings for key secondary outcomes were similar in patients with and without baseline metformin. Conclusion  This analysis suggests that the cardioprotective effect of dulaglutide is unaffected by the baseline use of metformin therapy.

Funder

Eli Lilly and Company

AstraZeneca

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2023 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3